Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Angiotensin Ii. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 3/20 | 0.79 |
| ▸ | AGTR2 | P50052 | 9/20 | 0.79 |
| ▸ | REN | P00797 | 3/20 | 0.62 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.60 |
| ▸ | ANPEP | P15144 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin Ii SCHEMBL3044639 | 0.99 | AGTR2 (0.81) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL1585377 | 0.97 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL13232382 | 0.97 | AGTR2 (0.84) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL2566771 | 0.97 | AGTR2 (0.84) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL1189 | 0.97 | AGTR2 (0.84) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL21408200 | 0.96 | AGTR2 (0.82) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL3465991 | 0.96 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL14990505 | 0.96 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL21267957 | 0.96 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL2183118 | 0.96 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423132-B2 | Method for the enrichment and characterization of phosphorylated peptides or proteins | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-09-09 | — | — | US | disclosed |
| US-20060014234-A1 | Method for the enrichment and characterization of phosphorylated peptides or proteins | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2006-01-19 | — | — | US | disclosed |
| WO-2005123758-A1 | METHOD FOR THE ENRICHMENT AND CHARACTERIZATION OF PHOSPHORYLATED PEPTIDES OR PROTEINS | MICHIGAN STATE UNIVERSITY (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014234-A1 | Method for the enrichment and characterization of phosphorylated peptides or proteins | PTMS, CHAMP1, ACP1 | AGTR1 4587/4885AGTR2 4689/4885REN 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.